Health

Zepp Unveils Zepp E, A New Stylish Line-Up of Wearables Designed with Wellness in Mind

SHENZHEN, China, Aug. 20, 2020 /PRNewswire/ -- Zepp, a professional-grade brand for the digital management of users' wellbeing, today unveiled a refreshed line-up of wearables, kicking off with the Zepp E series. With wellbeing at the top of everyone's agenda in 2020, the all-new Zepp E series ha...

2020-08-20 16:00 4661

Visiopharm granted patents for stain quality management in Tissue Biomarkers

HOERSHOLM, Denmark, Aug. 20, 2020 /PRNewswire/ -- Visiopharm®, the Denmark -based leader in artificial intelligence-driven image analysis, tissue mining, and precision pathology, has been granted patents in the US andEurope for an AI and image analysis-based approach to quantifying staining qualit...

2020-08-20 14:00 2396

Zymo Research Granted CE IVD Mark for Quick SARS-CoV-2 rRT-PCR Kit

IRVINE, California, Aug. 20, 2020 /PRNewswire/ -- Zymo Research announced that it was recently granted the CE IVD Mark for itsQuick SARS-CoV-2 rRT-PCR Kit. To obtain this certification the product had to comply with the Directive 98/79/EC of the European Parliament and of the Council of27 October...

2020-08-20 09:35 3594

US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma

SYDNEY, Aug. 20, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kazia's paxalisib (forme...

2020-08-20 08:35 8532

Harbour BioMed, Utrecht University, Erasmus Medical Center, Viroclinics-DDL and Kiadis Pharma Announce Collaboration to Develop Monoclonal Antibody, Natural Killer Cell Combination Approach to Treating COVID-19

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Aug. 19, 2020 /PRNewswire/ -- Harbour BioMed (HBM), and its partnersUtrecht University and Erasmus Medical Center, today announced a new research collaboration with Viroclinics-DDL and Kiadis Pharma (Euronext Amsterdam and Brussels: K...

2020-08-19 19:43 2894

Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market with its Expanded Portfolio and Geographic Presence

Jamjoom Pharmaceuticals is dedicated to being a center of excellence in healthcare and providing high-quality, safe, and effective products to meet the regional need JEDDAH, Saudi Arabia, Aug. 19, 2020 /PRNewswire/ -- Based on its recent analysis of the KSA emerging generic pharmaceuticals marke...

2020-08-19 16:00 1912

Global Entertainment Giant YOOZOO Aligns with Health Tech Company Plano to Tackle the Global Myopia Epidemic

SINGAPORE, Aug. 19, 2020 /PRNewswire/ -- Plano Pte Ltd (hereinafter, Plano), a Singapore-based health technology startup, and one of the world's leading providers of interactive entertainment, YOOZOO, have inked a Memorandum of Understanding to address the global burden of myopia inSingapore, the...

2020-08-19 12:00 4320

CStone Pharmaceuticals Reports Financial Results for the First Half of 2020

SUZHOU, China, Aug. 19, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today reported recent business highlights and financial resu...

2020-08-19 09:33 4186

Aon urges the re/insurance industry to bring capital closer to clients' needs as the firm launches its Virtual Reinsurance Renewal Season

Virtual event launches with former Danish Prime Minister Helle Thorning-Schmidt interview LONDON, Aug. 18, 2020 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm providing a broad range of risk, retirement and health solutions, today launches itsVirtual Reinsurance...

2020-08-18 23:37 20582

Mindray Sets A New Standard for Infusion Systems with the BeneFusion n Series

SHENZHEN, China, Aug. 18, 2020 /PRNewswire/ -- Mindray (SZSE: 300760), a leading provider of medical devices and solutions, has released its new generation infusion system,BeneFusion n Series. By rethinking safety, simplicity, interoperability and data synergy, the BeneFusion n Series sets a new...

2020-08-18 21:00 6500

athenahealth Earns the Frost & Sullivan 2020 RCM Company of the Year Award

athenahealth acclaimed by Frost & Sullivan for being at the forefront of solving critical RCM challenges and powering providers with agile solutions during the Covid-19 pandemic SANTA CLARA, California, Aug. 18, 2020 /PRNewswire/ -- Based on its recent analysis ofthe United States revenue cycle ...

2020-08-18 21:00 2511

Ascentage Pharma Releases 2020 Interim Results, Reporting the Company's First New Drug Application and Advances in Global Strategic Collaborations

SUZHOU, China and ROCKVILLE, Md., Aug. 18, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its interim results for the ...

2020-08-18 20:24 3404

Global Cord Blood Corporation to Report First Quarter Fiscal 2021 Financial Results

HONG KONG, Aug. 18, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results fo...

2020-08-18 19:00 11314

Innovent and Lilly Announce Expansion of TYVYT® (Sintilimab Injection) Licensing Agreement

SUZHOU, China and INDIANAPOLIS, Aug. 18, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2020-08-18 18:30 6095

Work Health Safety Expert warns Australian companies to be Vigilant.

NEWCASTLE, Australia, Aug. 18, 2020 /PRNewswire/ -- James Prout, CEO of Zokal Safety Australia, issued the following statement: "Australian business owners and directors should evaluate their safety systems and procedures as a matter of urgency," said work health safety specialist James Prout. "...

2020-08-18 07:17 2304

WuXi Biologics Records Excellent Interim Results

Revenue Up 21.0% Y-o-Y to RMB1,944.1 Million Net Profit Up 62.6% to RMB730.7 Million Profit Attributable to Owners of the Company Up 63.6% Y-o-Y to RMB736.1 Million Adjusted Net Profit Up 40.7% Y-o-Y to RMB734.0 Million Diluted EPS Up 55.9% Y-o-Y to RMB0.53 Adjusted Diluted EPS Up 38.5% Y-o-Y to RMB...

2020-08-18 00:51 2857

Start of bridging pharmacokinetic and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator O304

STOCKHOLM, Aug. 17, 2020 /PRNewswire/ -- In previous Phase I and Phase IIa clinical trials in healthy subjects and in type 2 diabetics, the small molecule AMPK activator compound O304 was administered as a suspension and with limited oral bioavailability. A novel formulation of O304 has now been ...

2020-08-17 22:13 2431

Sirtex Medical announces partnership with Magle Chemoswed

Collaboration grants Sirtex global use of innovative technology to develop novel imaging agent for interventional oncology WOBURN, Massachusetts, Aug. 17, 2020 /PRNewswire/ -- Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced a coll...

2020-08-17 20:00 2257

Great Big Story celebrates the innovative spirit of Singapore's Problem Solvers

HONG KONG, Aug. 17, 2020 /PRNewswire/ -- In its new Problem Solvers  series this month, Great Big Story meets the creators based inSingapore pushing the boundaries of technology and making innovative products with a social impact...

2020-08-17 12:55 3606

First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody

HANGZHOU, China and SHAOXING, China, Aug. 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody. ASC22(Envafolimab) Phase IIa clin...

2020-08-17 08:30 3662
1 ... 438439440441442443444 ... 562